Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Breo Fails To Reach Peak In SUMMIT Survival Study

This article was originally published in The Pink Sheet Daily

Executive Summary

The UK pharma had pinned much of its long-term hopes for Breo on successful results of SUMMIT, which compared the morbidity and mortality of COPD patients at increased risk of cardiovascular disease taking Breo versus placebo.

Advertisement

Related Content

Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Real World Superiority Data May Not Be Enough To Boost GSK's Breo In COPD
GSK Lays Out Five-Year Growth Strategy, Underpinned By Advair Generics
GSK Gets New Start For Breo With FDA Approval In Asthma
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle
“Real-World” Breo Study: A Q&A With GSK’s David Leather

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel